Prosecution Insights
Last updated: April 19, 2026

Examiner: WOOLWINE, SAMUEL C

Tech Center 1600 • Art Units: 1634 1637 1656 1681

This examiner grants 61% of resolved cases

Performance Statistics

61.1%
Allow Rate
+1.1% vs TC avg
897
Total Applications
+19.8%
Interview Lift
1376
Avg Prosecution Days
Based on 843 resolved cases, 2023–2026

Rejection Statute Breakdown

5.3%
§101 Eligibility
17.4%
§102 Novelty
36.1%
§103 Obviousness
28.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18569192 METHODS AND COMPOSITIONS FOR IDENTIFYING METHYLATED CYTOSINES Non-Final OA Illumina, Inc.
18462354 METHODS OF IDENTIFYING COMBINATIONS OF TRANSCRIPTION FACTORS Non-Final OA President and Fellows of Harvard College
18130523 METHODS, COMPOSITIONS, KITS AND SYSTEMS FOR SIGNAL-ON DETECTION OF NEUTRALIZATION TARGETS Non-Final OA PRESIDENT AND FELLOWS OF HARVARD COLLEGE
18457790 NUCLEIC ACID SEQUENCING-BY-SYNTHESIS (SBS) METHODS THAT COMBINE SBS CYCLE STEPS Non-Final OA Singular Genomics Systems, Inc.
17866240 STOICHIOMETRIC EXPRESSION OF MESSENGER POLYCISTRONS Non-Final OA California Institute of Technology
18219079 UNIVERSAL TEMPLATE STRANDS FOR ENZYMATIC POLYNUCLEOTIDE SYNTHESIS Non-Final OA MICROSOFT TECHNOLOGY LICENSING, LLC
18146748 NANOPHOTODETECTOR-BASED DEVICE FOR BIOMOLECULAR DETECTION Final Rejection Centre National de la Recherche Scientifique
17904301 Method and Device for Carrying out a qPCR Process Final Rejection Robert Bosch GmbH
18547495 METHODS FOR PROGNOSING, DIAGNOSING, AND TREATING COLORECTAL CANCER Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
17768527 BIOMATERIAL SENSOR SYSTEMS Non-Final OA The Regents of the University of Michigan
18139829 HIGH SENSITIVITY IMMUNOASSAY Non-Final OA Bio-Rad Laboratories, Inc.
17516215 METHOD OF OPTIMIZING EFFICACY OF THERAPEUTIC AGENT Non-Final OA Abbott Diabetes Care Inc.
17792630 METHOD AND SYSTEM FOR DNA DETECTION Non-Final OA Hitachi High-Tech Corporation
17758415 TRANSPOSITION-BASED DIAGNOSTICS METHODS AND DEVICES Final Rejection THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
17289490 BIOMARKER PANEL FOR DETERMINING MOLECULAR SUBTYPE OF LUNG CANCER, AND USE THEREOF Final Rejection SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
18261812 COMPOSITIONS, KITS AND METHODS FOR DIRECT AMPLIFICATION FROM CRUDE BIOLOGICAL SAMPLES Non-Final OA LIFE TECHNOLOGIES CORPORATION
18794356 METHODS FOR THE DIAGNOSIS OF BACTERIAL VAGINOSIS Non-Final OA Quest Diagnostics Investments LLC
18320411 ASSAY METHODS Non-Final OA MESO SCALE TECHNOLOGIES, LLC.
18575172 USE OF REAGENT FOR DETECTING PIR-HSA-120522 IN PLASMA IN PREPARATION OF LUNG CANCER SCREENING OR DIAGNOSIS KIT Non-Final OA WEST CHINA HOSPITAL, SICHUAN UNIVERSITY
18384971 Microfluidic Analysis System Non-Final OA Stokes Bio Limited
18308611 REVERSE TRANSCRIPTION-FREE QUANTITATIVE-DISCRETE POLYMERASE CHAIN REACTION FOR POST-PROCESS QUALITY CONTROL OF VESICULAR BIOLOGICS Non-Final OA Wayne State University
18538550 SPECIFIC DNA FRAGMENTS FOR SEX IDENTIFICATION OF MASTACEMBELUS ARMATUS, GENETIC sex MARKER PRIMERS AND APPLICATIONS THEREOF Final Rejection Guangzhou University
18514333 RARE NUCLEIC ACID DETECTION Non-Final OA Harbinger Health, Inc.
18128698 RARE NUCLEIC ACID DETECTION Non-Final OA Harbinger Health, Inc.
18286957 OPTIMIZED OLIGONUCLEOTIDE TX PROBE FOR A MULTIPLEXING ANALYSIS OF NUCLEIC ACIDS AND A MULTIPLEXING METHOD Non-Final OA BIOTYPE GMBH
18370325 MULTI-PRIMER AMPLIFICATION METHOD FOR BARCODING OF TARGET NUCLEIC ACIDS Non-Final OA Fluidigm Corporation
18463607 Rare Cell Analysis Using Sample Splitting And DNA Tags Non-Final OA Verinata Health, Inc.
18351061 METHODS AND DEVICES FOR ULTRASENSITIVE DIRECT DETECTION OF MICROORGANISMS Non-Final OA HelixBind, Inc.
18332520 SYSTEM AND METHOD FOR LIGAND-LIMITED NORMALIZING POLYMERASE CHAIN REACTION (LLN-PCR) Non-Final OA GTSeek, LLC
16630547 DNA TARGETS AS TISSUE-SPECIFIC METHYLATION MARKERS Final Rejection HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month